Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Follow-Up Questions
Takara Bio Inc のCEOは誰ですか？
Mr. Koichi Nakao は Takara Bio Inc の President で、2007 から在籍しています。
TKBIF の株価パフォーマンスは？
TKBIF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Takara Bio Inc の主な事業テーマや業界は？
Takara Bio Inc は Biotechnology 業界、セクターは Health Care に属しています。
